User profiles for "author:Jan Dörr"
Jan Rafael DörrMD/Phd, Pediatric Oncology, Charité Verified email at charite.de Cited by 1813 |
Characteristics of Susac syndrome: a review of all reported cases
J Dörr, S Krautwald, B Wildemann, S Jarius… - Nature Reviews …, 2013 - nature.com
In Susac syndrome, occlusions of microvessels—presumed to be mediated by an
autoimmune response to an as yet unknown antigen—lead to a characteristic clinical triad of …
autoimmune response to an as yet unknown antigen—lead to a characteristic clinical triad of …
Diagnostic criteria for Susac syndrome
I Kleffner, J Dörr, M Ringelstein, CC Gross… - Journal of Neurology …, 2016 - jnnp.bmj.com
Background Susac syndrome is characterised by the triad of encephalopathy with or without
focal neurological signs, branch retinal artery occlusions and hearing loss. Establishment of …
focal neurological signs, branch retinal artery occlusions and hearing loss. Establishment of …
[HTML][HTML] Exercise in multiple sclerosis--an integral component of disease management
A Döring, CF Pfueller, F Paul, J Dörr - Epma journal, 2012 - Springer
Multiple sclerosis (MS) is the most common chronic inflammatory disorder of the central
nervous system (CNS) in young adults. The disease causes a wide range of symptoms …
nervous system (CNS) in young adults. The disease causes a wide range of symptoms …
Senescence-associated reprogramming promotes cancer stemness
M Milanovic, DNY Fan, D Belenki, JHM Däbritz, Z Zhao… - Nature, 2018 - nature.com
Cellular senescence is a stress-responsive cell-cycle arrest program that terminates the
further expansion of (pre-) malignant cells,. Key signalling components of the senescence …
further expansion of (pre-) malignant cells,. Key signalling components of the senescence …
Synthetic lethal metabolic targeting of cellular senescence in cancer therapy
Activated oncogenes and anticancer chemotherapy induce cellular senescence, a terminal
growth arrest of viable cells characterized by S-phase entry-blocking histone 3 lysine 9 …
growth arrest of viable cells characterized by S-phase entry-blocking histone 3 lysine 9 …
Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin
O Aktas, S Waiczies, A Smorodchenko… - The Journal of …, 2003 - rupress.org
Statins, known as inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
reductase, exhibit numerous functions related to inflammation, such as MHC class II down …
reductase, exhibit numerous functions related to inflammation, such as MHC class II down …
Distinct lesion morphology at 7-T MRI differentiates neuromyelitis optica from multiple sclerosis
T Sinnecker, J Dörr, CF Pfueller, L Harms, K Ruprecht… - Neurology, 2012 - AAN Enterprises
Objective: To investigate distinct white matter and cortical gray matter pathology in
neuromyelitis optica spectrum disorders (NMOSDs) and multiple sclerosis (MS) at 7-T MRI in …
neuromyelitis optica spectrum disorders (NMOSDs) and multiple sclerosis (MS) at 7-T MRI in …
[PDF][PDF] Tumor stroma-derived TGF-β limits myc-driven lymphomagenesis via Suv39h1-dependent senescence
Activated RAS/BRAF oncogenes induce cellular senescence as a tumor-suppressive barrier
in early cancer development, at least in part, via an oncogene-evoked DNA damage …
in early cancer development, at least in part, via an oncogene-evoked DNA damage …
Lower motor neuron loss in multiple sclerosis and experimental autoimmune encephalomyelitis
Objective Multiple sclerosis (MS) is considered a chronic inflammatory and demyelinating
disease of the central nervous system. Evidence that axonal and neuronal pathology …
disease of the central nervous system. Evidence that axonal and neuronal pathology …
[HTML][HTML] Association of retinal and macular damage with brain atrophy in multiple sclerosis
J Dörr, KD Wernecke, M Bock, G Gaede, JT Wuerfel… - PLoS …, 2011 - journals.plos.org
Neuroaxonal degeneration in the central nervous system contributes substantially to the
long term disability in multiple sclerosis (MS) patients. However, in vivo determination and …
long term disability in multiple sclerosis (MS) patients. However, in vivo determination and …